| Leukemia, Myelocytic, Acute
Vanflyta vs Xospata
Side-by-side clinical, coverage, and cost comparison for leukemia, myelocytic, acute.Deep comparison between: Vanflyta vs Xospata with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXospata has a higher rate of injection site reactions vs Vanflyta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xospata but not Vanflyta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Vanflyta
Xospata
At A Glance
Oral
Once daily
FLT3 inhibitor
Oral
Daily
FLT3 inhibitor
Indications
- Leukemia, Myelocytic, Acute
- Leukemia, Myelocytic, Acute
Dosing
Leukemia, Myelocytic, Acute Induction: 35.4 mg orally once daily on Days 8 to 21 of each 28-day cycle, up to 2 cycles with cytarabine and anthracycline; Consolidation: 35.4 mg once daily on Days 6 to 19 of each cycle, up to 4 cycles with high-dose cytarabine; Maintenance: 26.5 mg once daily (escalate to 53 mg on Day 15 if QTcF <=450 ms), continuous once-daily with no break for up to 36 cycles.
Leukemia, Myelocytic, Acute 120 mg orally once daily with or without food; in the absence of disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for a clinical response.
Contraindications
- Severe hypokalemia
- Severe hypomagnesemia
- Long QT syndrome
- History of ventricular arrhythmias or torsades de pointes
- Hypersensitivity to gilteritinib or any of the excipients
Adverse Reactions
Most common (>=10%) Febrile neutropenia, diarrhea, mucositis, nausea, sepsis, abdominal pain, vomiting, neutropenia, headache, upper respiratory tract infection, hypertransaminasemia, thrombocytopenia, fungal infection, herpesvirus infection, decreased appetite, epistaxis, insomnia, electrocardiogram QT prolonged, anemia, dyspepsia, eye irritation.
Serious Febrile neutropenia, sepsis, fungal infections, brain edema, pneumonia, cerebral infarction, acute respiratory distress syndrome, pulmonary embolism, ventricular dysfunction, cardiac arrest.
Most common (>=10%) transaminase increased, myalgia/arthralgia, fatigue/malaise, fever, mucositis, edema, rash, noninfectious diarrhea, dyspnea, nausea, cough, constipation, eye disorders, headache, dizziness, hypotension, vomiting, renal impairment, abdominal pain, neuropathy, insomnia, dysgeusia
Serious differentiation syndrome, posterior reversible encephalopathy syndrome, prolonged QT interval, pancreatitis
Pharmacology
Quizartinib is a small molecule inhibitor of the receptor tyrosine kinase FLT3; it and its active metabolite AC886 bind the ATP binding domain of FLT3, inhibiting kinase activity and downstream FLT3 receptor signaling, thereby blocking FLT3-ITD-dependent cell proliferation.
Gilteritinib is a small molecule inhibitor of multiple receptor tyrosine kinases, including FLT3; it inhibits FLT3 receptor signaling and proliferation in cells expressing FLT3-ITD and FLT3 tyrosine kinase domain mutations, and induces apoptosis in leukemic cells expressing FLT3-ITD.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Vanflyta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Xospata
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (3/12) · Qty limit (12/12)
UnitedHealthcare
Vanflyta
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Xospata
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Vanflyta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Xospata
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Acute Myeloid Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Acute Myeloid Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
VanflytaView full Vanflyta profile
XospataView full Xospata profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.